| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -5,465,751 | -5,469,446 | 25,411,055 | NaN |
| Depreciation and amortization | 956,401 | 964,422 | 960,850 | 2,924,303 |
| Net loss | NaN | NaN | NaN | -19,310,155 |
| Non-cash lease expense, net of lease payments | -19,553 | -2,301 | 2,842 | 2,970 |
| Share-based payments for services | 57,106 | 58,318 | 167,388 | 587,285 |
| Equity based compensation | 451,381 | 443,275 | 440,506 | 1,470,491 |
| Common stock contributed to 401 plan | 61,788 | 57,262 | 53,807 | 164,510 |
| Shares issued for settlement of clinic development costs | NaN | NaN | 350,885 | NaN |
| Shares issued for settlement of clinical development costs | 431,663 | -302,758 | NaN | 350,885 |
| Loss on patent impairment | 22,257 | 12,851 | 4,963 | 13,312 |
| Prepaid expenses | 199,111 | 183,258 | 28,676 | 13,874 |
| Supplies used for r&d and manufacturing | 26,905 | -55,677 | -350,834 | -622,831 |
| Deposits | -720 | 0 | 7,585 | -4,000 |
| Accounts payable | -101,031 | 71,171 | -445,154 | 2,444 |
| Accrued expenses | -26,240 | -226,360 | 181,218 | -60,490 |
| Due to employees | -202,780 | 143,555 | -252,932 | 806,214 |
| Proceeds from related party loans | NaN | NaN | 0 | NaN |
| Net cash used in operating activities | -4,022,389 | -4,022,105 | -4,670,523 | -12,449,214 |
| Payments of related party loans | NaN | NaN | 0 | NaN |
| Purchases of property and equipment | 0 | 0 | 5,155 | 32,954 |
| Proceeds from notes payable | NaN | NaN | 0 | 350,000 |
| Expenditures for patent costs | NaN | NaN | 0 | 0 |
| Proceeds from the purchase of stock by officers and directors | NaN | NaN | NaN | 0 |
| Net cash used in investing activities | 0 | 0 | -5,155 | -32,954 |
| Proceeds from issuance of common stock and pre-funded warrants | 0 | 0 | 15,730,800 | 12,560,300 |
| Payments of stock issuance costs | 0 | 158,115 | 1,594,947 | 1,531,832 |
| Payments of notes payable | NaN | NaN | 0 | 350,000 |
| Proceeds from the purchase of stock by officers and directors | 200,001 | 49,999 | -219,995 | NaN |
| Payments on obligations under finance leases | 564,462 | 545,657 | 519,566 | 1,491,617 |
| Net cash (used in) provided by financing activities | -364,461 | -653,773 | 13,836,282 | 9,536,851 |
| Net decrease in cash and cash equivalents | -4,386,850 | -4,675,878 | 9,160,604 | -2,945,317 |
| Cash and cash equivalents, beginning of period | 6,277,582 | 10,953,460 | 4,738,173 | NaN |
| Cash and cash equivalents, end of period | 1,890,732 | 6,277,582 | 10,953,460 | NaN |
CEL SCI CORP (CVM)
CEL SCI CORP (CVM)